患有转移性副甲状腺癌的患者的长期存活率,其中包含EGFR敏感突变:一个病例报告
Yushi Ying1,2,3, Hanning Li1,2,3, Wenfei Xia1
1Department of Thyroid and Breast Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China.
The Journal of international medical research
|July 25, 2024
概括
副甲状腺癌 (PC) 是一种罕见且具有攻击性的癌症. 在基因测序的指导下,用anlotinib进行向治疗,在患有转移性PC的患者中显示出生存益处.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 副甲状腺癌 (PC) 是一种罕见的内分泌恶性瘤,预后不佳.
- 目前的化疗和放射疗法等治疗方法对晚期PC的疗效有限.
相关概念视频
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K